HRI调控的转录因子ATF4激活BCL11A转录以沉默胎儿血红蛋白表达
该研究通过CRISPR-Cas9功能缺失筛选发现ATF4是新的γ-珠蛋白调控因子,ATF4通过结合BCL11A增强子促进增强子-启动子接触直接刺激BCL11A转录,从而抑制γ-珠蛋白;HRI缺陷小鼠Bcl11a水平正常提示种属选择性调控,因小鼠Bcl11a增强子中类似ATF4基序基本非必需。
要点
- ATF4是HRI下游的γ-珠蛋白调控因子,直接激活BCL11A转录
- ATF4通过结合BCL11A增强子并促进增强子-启动子接触发挥作用
- HRI-ATF4-BCL11A-γ-珠蛋白构成线性信号通路,小鼠模型存在种属差异
核心结论
- HRI通过ATF4激活BCL11A转录进而沉默胎儿血红蛋白,构成线性信号通路。
- HRI缺陷小鼠Bcl11a水平正常提示种属选择性调控。
研究设计与样本
- 在人红系祖细胞中进行CRISPR-Cas9引导的功能缺失筛选。
- 使用HRI缺陷小鼠观察Bcl11a水平。
主要发现
- 筛选鉴定转录因子ATF4为新的γ-珠蛋白调控因子。
- ATF4直接刺激BCL11A转录,通过结合其增强子并促进增强子-启动子接触。
- HRI缺陷小鼠Bcl11a水平正常,小鼠Bcl11a增强子中类似ATF4基序基本非必需。
临床怎么用
- HRI可能作为药物靶点用于提升胎儿血红蛋白水平。
- 小鼠模型在珠蛋白基因调控研究中的适用性有限。
局限性
- HRI缺陷小鼠Bcl11a水平正常提示种属差异,限制小鼠模型外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reactivation of fetal hemoglobin remains a critical goal in the treatment of patients with sickle cell disease and β-thalassemia. Previously, we discovered that silencing of the fetal γ-globin gene requires the erythroid-specific eIF2α kinase heme-regulated inhibitor (HRI), suggesting that HRI might present a pharmacologic target for raising fetal hemoglobin levels. Here, via a CRISPR-Cas9-guided loss-of-function screen in human erythroblasts, we identify transcription factor ATF4, a known HRI-regulated protein, as a novel γ-globin regulator. ATF4 directly stimulates transcription of BCL11A, a repressor of γ-globin transcription, by binding to its enhancer and fostering enhancer-promoter contacts. Notably, HRI-deficient mice display normal Bcl11a levels, suggesting species-selective regulation, which we explain here by demonstrating that the analogous ATF4 motif at the murine Bcl11a enhancer is largely dispensable. Our studies uncover a linear signaling pathway from HRI to ATF4 to BCL11A to γ-globin and illustrate potential limits of murine models of globin gene regulation.
引用
- Huang P, Peslak SA, Lan X, et al. The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression. Blood. 2020. PMID: 32299090. doi:10.1182/blood.2020005301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。